CYP20A1

Across TCGA pan-cancer cohorts, CYP20A1 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of CYP20A1’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where CYP20A1 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types CYP20A1 is over-expressed in tumor, although a few such as CCRCC and LSCC show the opposite, repressed pattern.

CCRCC, LSCC, and LUAD are the cancer types where CYP20A1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CYP20A1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	III,IV	−0.433	<.001	11	view →
LSCC	Male	II,III,IV	−0.364	<.001	8	view →
LUAD	Male	II,III,IV	−0.202	<.001	8	view →
COAD	All	II,III,IV	−0.142	<.001	8	view →
PDAC	Male	All	−0.591	<.001	6	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

CYP20A1–CCRCC

Open the CCRCC breakdown →